Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study-Reference-Cited by-同舟云学术

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study

Published:2021-06-01 Issue:2 Volume:87 Page:794-800
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

van Wyk Jean,Ait-Khaled Mounir,Santos Jesus,Scholten Stefan,Wohlfeiler Michael,Ajana Faïza,Jones Bryn,Nascimento Maria-Claudia,Tenorio Allan R.,Smith Don E.,Wright Jonathan,Wynne Brian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference23 articles.

1. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study;Achhra;HIV Med.,2016

2. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis;Nansseu;Epidemiology,2018

3. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials;Sax;Clin Infect Dis.,2020

4. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide;Schafer;Open Forum Infect Dis.,2019

5. Dolutegravir plus two different prodrugs of tenofovir to treat HIV;Venter;N Engl J Med.,2019

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study;AIDS Research and Human Retroviruses;2024-01-05

2. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting;Journal of Antimicrobial Chemotherapy;2023-10-24

3. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials;Frontiers in Reproductive Health;2023-09-18

4. Associations of HIV and antiretroviral therapy with gestational diabetes in South Africa;AIDS;2023-08-02

5. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years;AIDS Research and Human Retroviruses;2023-07-05